A Physician-Led Approach to Metabolic Liver Health

Fatty liver disease, now increasingly referred to as Metabolic Associated Fatty Liver Disease (MAFLD), is one of the most common — and most under-recognised — manifestations of metabolic dysfunction.
In many individuals, fatty liver develops silently and is often discovered incidentally on imaging or routine blood tests. When addressed early, progression is frequently preventable and, in many cases, reversible.

What Is Fatty Liver Disease?

MAFLD occurs when excess fat accumulates within liver cells, impairing liver metabolism and function.
It is closely linked to:

  • Insulin resistance
  • Visceral and ectopic fat accumulation
  • Dyslipidaemia
  • Prediabetes or type 2 diabetes

Fatty liver exists on a spectrum, ranging from simple steatosis to inflammatory and fibrotic stages.

Why Fatty Liver Matters

Although often asymptomatic, fatty liver is not a benign finding.

  • It reflects systemic metabolic dysfunction
  • It increases cardiovascular risk
  • It can progress to liver inflammation and fibrosis
  • It is strongly associated with insulin resistance and diabetes

Fatty liver is best understood as a metabolic signal, not an isolated liver condition.

Fatty liver may be present even when liver enzymes are normal. Risk factors include:

  • Central or abdominal obesity
  • Insulin resistance or prediabetes
  • Type 2 diabetes
  • Elevated triglycerides or low HDL cholesterol
  • Hypertension
  • Sedentary lifestyle
  • Rapid weight gain or loss

Assessment focuses on identifying metabolic drivers and excluding advanced disease. It may include:

  • Review of imaging reports (ultrasound, CT, or MRI when available)
  • Interpretation of liver enzymes and metabolic markers
  • Assessment of insulin resistance and lipid profile
  • Evaluation of alcohol intake and medications
  • Risk stratification for fibrosis when indicated

Testing is used to guide management and determine urgency — not to alarm unnecessarily.

Fatty liver does not improve without addressing underlying metabolic dysfunction. Key drivers include:

  • Insulin resistance
  • Visceral fat accumulation
  • Dietary excess or mismatch
  • Physical inactivity
  • Sleep disruption

Targeting these factors is central to improvement.

Care plans may include:

  • Nutritional strategies supporting liver fat reduction
  • Gradual, sustainable weight and body composition changes
  • Physical activity to improve hepatic insulin sensitivity
  • Management of associated metabolic conditions
  • Medical therapy when appropriate

The focus is liver recovery and long-term metabolic health, not short-term enzyme normalisation alone.

Progress is monitored using:

  • Trends in liver enzymes and metabolic markers
  • Imaging follow-up when indicated
  • Overall metabolic and cardiovascular risk profile

Early improvement often reflects systemic metabolic recovery.

Fatty liver frequently coexists with:

  • Insulin resistance and prediabetes
  • Type 2 diabetes
  • Cardiovascular disease risk factors
  • Hormonal imbalance

Care is coordinated across programs to address shared drivers.

Frequently Asked Questions

Q1 :Can fatty liver be reversed?

In most cases, yes — particularly when addressed early through metabolic intervention.

No. Most patients improve through lifestyle and metabolic optimisation alone, while others may require medical therapy.

No. Fatty liver can be present despite normal liver enzymes.

Request a Consultation